Join us as we showcase accomplishments and discuss opportunities for the future of the BioHealth industry in the BioHealth Capital Region.
This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Paragon Bioservices, INOVA, University System of Maryland and MedImmune/AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum — a catalyst for public-private, academia-industry, and seasoned-rising stars to join forces for the good of the region. We are excited to bring you an exceptional line up of speakers. The program will feature sessions that focus on Advancing Science and Accelerating Innovation.
Immunomic Therapeutics’ is pleased to announce five finalists for the Cancer Discovery Incubator Award.
Immunomic’s unique incubator award offers the selected innovator an opportunity to develop a proof-of-concept experiment in their laboratories. Additionally, the winner will be gifted funding, lab equipment and a unique mentorship with the Immunomic executive team for one year. The goal is to empower the innovator to conduct proof-of-concept experiments and ultimately, help the winner attract funding, partnerships, and fuel growth.
Gaithersburg-based NexImmune, a biotech developing immunotherapy treatments for cancer, has been acquired by a consortium of big-name biotech veterans and investors.
MagBio Genomics, Inc. announces the launch of its new Blood STASIS™ 21- ccfDNA tube for venous whole blood collection and room temperature stabilization of circulating cell-free DNA (ccfDNA).
The Blood STASIS 21-ccfDNA is a direct draw whole blood collection system that contains a proprietary reagent that prevents post-collection release of genomic DNA from white blood cells, resulting in efficient and accurate recovery of ccfDNA with minimal genomic DNA (gDNA) contamination leading to more informative and quality data.
Thursday, Feb 23 Vigilant Bioservices Open House (UMB Biopark) Come explore our Biorepository then join us for the UMB BioPark Holiday Happy Hour! Tours are from 1:00-5:00pm
Vigilant Bioservices provides GMP storage solutions for Biotech organizations, including outsourced temperature controlled storage and risk mitigation/business continuity services.
If you demand a return on the cost of quality, we offer peace of mind knowing your biomaterials are safe.
OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital (“3E”).
The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease (GvHD). OncoImmune will continue clinical testing of its lead clinical product, CD24Fc, in a Phase II trial for the prevention of acute GvHD following myeloablative allogeneic hematopoietic stem cell transplant. CD24Fc has received orphan drug designation for GvHD in both the US and Europe. The funding will also support development of other immuno-oncology (IO) assets with a focus on solid tumor targeting monoclonal antibodies, cancer vaccines, and immunotherapy-related adverse events.
Get a sneak peek of the country’s largest, most advanced mobile STEM lab. Please join us for an Open House onboard MdBio’s new mobile laboratory, the Mobile eXploration Lab.
Tuesday, March 7, 2017 | 4 – 6 PM
Johns Hopkins University Montgomery Parking Lot
9601 Medical Center Drive, Rockville, MD 20850
Corner of Key West Avenue & Broschart Road. Ample free parking available.
Join Sinai Hospital BioIncubator on Thursday, February 23, 2017, for the second seminar of our Distinguished Speaker Series, sponsored by TEDCO. Keynote speaker Jeff Gibbs, a member of our Innovation Council, will be speaking about the FDA and regulatory affairs.
Event information: When: Thursday, February 23, 2017 from 4:00-5:30pm Location: 2401 W. Belvedere Ave., Baltimore, MD 21215 Room: Phyllis and Leonard J. Attman Board Room (Sinai Hospital Board Room) Parking: Please park in the general hospital parking visitor’s lot, located outside the main entrance of the hospital. This will give you the easiest access to the Phyllis and Leonard J. Attman Board Room.
About The Speaker
Mr. Gibbs is a Director at Hyman, Phelps & McNamara, P.C., Washington, DC, the largest law firm specializing in Food and Drug Administration (FDA) issues. Prior to entering private practice, he served as Associate Chief Counsel for Enforcement at FDA. Mr. Gibbs is currently the chairman of the Food and Drug Law Institute, and he previously served as a member of the George Mason University Human Subjects Review Board. He has written and spoken extensively on FDA issues. Mr. Gibbs graduated from Princeton University and New York University School of Law.
The Washington DC/Baltimore Chapter of Women In Bio is presenting a program to learn about how bioscience discoveries move from the bench to the market. The route from discovery to market is not linear. Our panelists will relay their experiences with clinical trials, manufacturing, and marketing and will discuss how each of these aspects interacts along the way. Whether you are looking to enter the world of bench to market or are just curious about the process, this will be an informative and fun event. Moderated by Lynn Johnson Langer, Program Director, Sr. Lecturer, Johns Hopkins University, our panel includes the following individuals:
Neta Nelson – Associate Director, Clinical Operations & Project Management, Technical Resources International, Inc.
Maura Kahn – Vice President, Business Development and Marketing, Noxilizer, Inc.
Kathy Webb – Senior Director GMP Operations, Paragon Bioservices, Inc.
Date/Time: Thursday, February 23, 2017 6:00 p.m. – 8:00 p.m. EST
Venue: Johns Hopkins University – Montgomery Campus 106-110 A&R Building 9601 Medical Center Drive Rockville, MD 20850
The products that make cities “smart” will be developed, tested and perhaps scaled in our backyard.
A partnership of the Herndon-based Center for Innovative Technology, D.C.-based Smart City Works and 22 CityLink, the master developer of the Gramercy District smart city planned for Ashburn, is accepting applications for its initial cohort of companies in Smart City Works @ Herndon.
Welcome to the fifth edition of the U.S. Chamber International IP Index, “The Roots of Innovation.” This year’s index recognizes the indispensable role of intellectual property (IP), in facilitating innovative and creative activity on a socially transformative scale.
Each economy in the Index presents a unique IP profile. As this Index has grown from 11 economies in its first edition to 45 in the current publication, it has become exceedingly clear that just as elections matter, so do IP policy choices. These choices are not simply a matter of East versus West, developed versus less-developed, or rich versus poor. Rather, the Index represents a broad spectrum of sovereign policy choices. Those choices have important consequences for each economy’s innovative and creative success, and for the collective welfare of all the world’s citizens.
The Big Idea CONNECTpreneur Forum is a Community of over 5000 CEOs, Entrepreneurs, VCs and angels, CXOs and other business leaders in the Mid-Atlantic Region.
Each quarterly CONNECTpreneur Forum mashes up 400+ top founders, investors and business leaders for a morning breakfast event featuring awesome networking, newsmaking speakers, and a showcase of 7-8 exciting early stage companies.
This UNIQUE EVENT is like NONE OTHER in our region, due to the high quality of our attendees and participants, as well as our programming and unprecedented networking.
Most of the attendees are INVITATION ONLY, and we strictly limit service provider participation in order to maximize the experience for our Attendees and Sponsors.
This one-day event will highlight the latest trends in medical devices and technologies and feature resources in the state that help bring products from invention to market. Topics include bioelectronics, cybersecurity for medical devices, convergence of devices and drugs, big data, robotic prosthetics, and additive manufacturing applications. Organizations representing Maryland innovation, entrepreneurial, funding, regulatory, and product scale-up resources will be there to discuss ways that they work with the medical device community.
This event is sponsored by the University of Maryland Robert E. Fischell Institute for Biomedical Devices, Maryland Manufacturing Extension Partnership, the Maryland Department of Commerce, Federal Laboratory Consortium (FLC), FLC Mid-Atlantic Region, National Institute for Standards and Technology Manufacturing Extension Partnership , and TEDCO.
Niche-specific content is usually not readily available through regular generic search engines. One example is the academic and scholarly content. While running a search query about an academic topic through a generic search engine such as Google would probably render fairly decent results, it, however, usually takes digging into so much fluff before finally landing on relevant results. This is where having access to topic-specific search engines comes in handy. Such search engines do not only provide specific content tailored to the topic under study but their content is more likely to be reliable and authoritative. To this end, we have compiled this list of excellent academic search engines that teachers, student researchers and academics can use to quickly locate and access scholarly works and publications. We have only included what we believe are the most relevant and popular titles out there. If you have other suggestions to add to the list please share with us on our Facebook page.
The Office of the National Coordinator for Health Information Technology (ONC), in collaboration with the Chamber of Digital Commerce announces a health standards and data innovation Code-a-Thon. Code-a-Thon contestants will use open source distributed ledger technology and health-specific standards to address one of the following health IT Tracks:
What’s the best way to build a startup? Bootstrap it, raise little or no VC funding, and (ideally) sell it for hundreds of millions—or billions—of dollars, according to two venture capitalists.
That’s what they did at least. Andrew Farquharson, now the managing director of InCube Ventures in San Jose, CA, was the chief operating officer of Almeda, CA-based Operon Technologies when it sold to European nucleic acid company Qiagen in an all-stock deal worth around $110 million in 2000. Farquharson and his co-founders tried, but failed, to raise venture funding and instead were able to bootstrap.
Illumina Accelerator, the genomics-based company creation engine focused on building early stage genomics startups welcomes three new companies to its fifth funding cycle. Since its inception in 2014, Illumina Accelerator has helped startups validate and create next-generation sequencing applications and bring those solutions to market. To date, Illumina Accelerator has invested in 13 startups working to advance breakthrough applications in genomics.
After listening to hundreds of startup pitches, and reading even more business plans, most new venture investors develop their own favorite list of “red flags” that signal the beginning of the end of their interest. Others, like Guy Kawasaki, have irreverently called some of these “entrepreneur lies,” but I prefer to think of them as innocent enhancements or omissions that can kill your deal.
At any rate, here is my own list of red flags, from my years of experience advising and investing in aspiring entrepreneurs, which cause me to lose interest and start looking for a way out the door:
In order to address the unmet needs and create opportunities that benefit patients with rare disease in India, a group of volunteers created a not-for-profit organization named Organization for Rare Diseases India (ORDI; www.ordindia.org). ORDI plans to represent the collective voice and advocate the needs of patients with rare diseases and other stakeholders in India. The ORDI team members come from diverse backgrounds such as genetics, molecular diagnostics, drug development, bioinformatics, communications, information technology, patient advocacy and public service. ORDI builds on the lessons learned from numerous similar organizations in the USA, European Union and disease-specific rare disease foundations in India. In this review, we provide a background on the landscape of rare diseases and the organizations that are active in this area globally and in India. We discuss the unique challenges in tackling rare diseases in India, and highlight the unmet needs of the key stakeholders of rare diseases. Finally, we define the vision, mission, goals and objectives of ORDI, identify the key developments in the health care context in India and welcome community feedback and comments on our approach.
If you’re learning how to develop CRADAs or have ever wished for an easy guide, take our newest free e-course! “The CRADA Developer’s Guide” is now available to take at your own pace in our Learning Center!
The CRADA is one of federal tech transfer’s most powerful tools. This course helps you understand the process and considerations for developing and managing a good CRADA, including:
When to choose a CRADA How to craft a CRADA Managing a CRADA Troubleshooting strategies.
A group of scientists and their supporters are set to march Sunday in Boston’s Copley Square in an event they’ve dubbed “a rally to stand up for science” in the Trump years.
Inside a large nearby convention center, meanwhile, the annual meeting of the American Association for the Advancement of Science (AAAS), the United States’ largest general scientific society, has featured speeches and panel sessions further underscoring the sense that under President Trump, scientists could face wide-ranging political conflicts and challenges, and will have to decide how to meet them.
A record number of biotechnology, life sciences and other tech-related companies with a presence in New Jersey stand to benefit from private investments spurred in part by tax credits approved by state officials last year — a sign the Garden State continues to serve as the nation’s medicine chest.
The New Jersey Economic Development Authority announced Tuesday it has approved 251 applications from “angel investors” who are eligible for state income-tax credits to help offset the more than $96 million in private funding they funneled to Garden State tech firms during 2016 — the highest annual total since the program launched three years ago.
Tesla and SpaceX founder Elon Musk has a suggestion for humans who want to stay relevant in a future of artificial intelligence: merge with the machines.
“Over time I think we will probably see a closer merger of biological intelligence and digital intelligence,” Musk said at the World Government Summit in Dubai, according to CNBC. “It’s mostly about bandwidth, the speed of the connection between your brain and the digital version of yourself, particularly output.”
The Baltimore Ravens Innovation Challenge at Light City is a live pitch competition where six startup companies will present in front of a panel of judges to win a year-long marketing package with a value of $200,000 from the Baltimore Ravens.
The Competition will take place during the SocialLab@LightCity – April 6, 2017. Labs@LightCity will bring together national and local thought leaders and engaged, inspired citizens from diverse backgrounds to explore cutting edge concepts for sparking social change.
A discounted ticket for friends of Light City is now available for $99 (a discount of $50). Use the code LCFriends50 when checking out and your discount will be automatically applied to your registration. You may also share the code with friends who you believe would want to join the conversation, vote during the Pitch Competition, learn and have a real impact on the Labs, Baltimore, and beyond!
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
